RA Capital Healthcare Fund LP 4
4 · Artiva Biotherapeutics, Inc. · Filed Jul 20, 2026
Research Summary
AI-generated summary of this filing
Artiva (ARTV) 10% Owner RA Capital Management Buys Stock
What Happened RA Capital Management, L.P. — reported as a 10% owner and investment manager to several funds/accounts — acquired a total of 160,354 shares of Artiva Biotherapeutics (ARTV) in open‑market purchases. The bulk was 152,472 shares on 2026-07-16 at a weighted average price of $8.93 (≈ $1,361,575). An additional 7,882 shares were bought on 2026-07-17 at a weighted average price of $8.95 (≈ $70,544). Combined consideration for the two-day activity was about $1,432,119. These were purchases (institutional buys), which some investors view as a bullish signal, though the filing itself does not state motive.
Key Details
- Transaction dates and reported prices:
- 2026-07-16: 152,472 shares at weighted avg $8.93 (price range reported per footnote: $8.79–$9.00).
- 2026-07-17: 7,882 shares at weighted avg $8.95 (price range reported per footnote: $8.88–$9.00).
- Total shares purchased: 160,354; total reported value ≈ $1,432,119.
- Shares owned after the transactions: not specified in the provided filing details.
- Filing timeliness: Form 4 was filed on 2026-07-20 for trades dated 7/16 and 7/17 — the filing appears late (reported after the two‑business‑day window), which reduces near‑term transparency.
- Notable footnotes:
- Purchases were executed in multiple transactions and reported as weighted averages; RA Capital offers to provide per‑price breakdowns on request.
- RA Capital Management, L.P. acts as adviser to several entities (RA Capital Healthcare Fund, Nexus Fund, Nexus Fund III, and a separately managed account); specific lots are held directly by those funds/accounts.
- The adviser and related parties disclaim beneficial ownership except for their pecuniary interest.
- Laura Stoppel, a Partner at the Adviser, serves on Artiva’s board of directors (disclosed in remarks).
Context This disclosure reflects institutional fund buying by a 10% owner/adviser rather than trading by an Artiva executive. Institutional purchases can indicate manager conviction but do not guarantee future stock performance. The filing’s weighted‑average pricing and fund-level structure mean the activity represents pooled fund decisions across multiple transactions.
Insider Transaction Report
- Purchase
Common Stock
[F1][F2][F3]2026-07-16$8.93/sh+152,472$1,361,575→ 16,970,045 total(indirect: See footnotes) - Purchase
Common Stock
[F4][F2][F3]2026-07-17$8.95/sh+7,882$70,544→ 16,977,927 total(indirect: See footnotes)
- 264,571(indirect: See footnotes)
Common Stock
[F2][F5] - 826,832(indirect: See footnotes)
Common Stock
[F2][F6] - 68,320(indirect: See footnotes)
Common Stock
[F2][F7]
Footnotes (7)
- [F1]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.79 to $9.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- [F2]RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
- [F3]Held directly by the Fund.
- [F4]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.88 to $9.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- [F5]Held directly by the Nexus Fund.
- [F6]Held directly by Nexus Fund III.
- [F7]Held directly by the Account.